Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4643 - Combined immunoscore for prognostic stratification of early stage NSCLC patients


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Giulia Pasello


Annals of Oncology (2019) 30 (suppl_5): v585-v590. 10.1093/annonc/mdz258


G. Pasello1, A. Boscolo2, F. Fortarezza3, F. Lunardi3, L. Urso2, S. Frega1, G. Comacchio4, L. Bonanno1, V. Guarneri5, F. Rea6, F. Calabrese3, P.F. Conte2

Author affiliations

  • 1 Oncology 2, Istituto Oncologico Veneto IRCCS, 35128 - Padua/IT
  • 2 Department Of Surgery, Oncology And Gastroenterology, Università degli Studi di Padova, 35128 - Padua/IT
  • 3 Pathology Unit, Department Of Cardiac,thoracic, Vascular Sciences And Public Health, Università degli Studi di Padova, 35128 - Padua/IT
  • 4 Thoracic Surgery Unit, Department Of Cardio-thoracic And Vascular Sciences, University of Padova, 35128 - Padua/IT
  • 5 Surgery, Oncology And Gastroenterology, Istituto Oncologico Veneto IRCCS, 35128 - Padua/IT
  • 6 Thoracic Surgery Unit, Department Of Cardio-thoracic And Vascular Sciences, Università degli Studi di Padova, 35128 - Padua/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4643


Tumor infiltrating lymphocytes (TILs) and PD-L1 expression have been previously associated with early stage NSCLC prognosis. Most data refer to intra-tumoral (IT) lymphocytes, while evidence on the prognostic role of the tumor immune microenvironment (TME) as a whole is lacking. Moreover, a combined immuno-score (IS) including more than two markers, is currently not available. We investigated the prognostic impact of PD-L1 expression and different immune cell infiltrates (CD3+CD4+, CD3+CD8+ T-lymphocytes and CD68+ macrophages) at peritumoral (PT) and IT level.


Surgical specimens from chemo-naive stage II-III NSCLC patients radically resected between 2015 and 2017 were analyzed. Immunohistochemistry was carried out to evaluate PD-L1 expression (low <50%, high³50%), and to quantify IT, PT and total CD3+CD4+, CD3+CD8+ T-lymphocytes and CD68+ macrophages. The impact of single marker and of a combination of multiple significant markers on overall survival (OS) was investigated.


Preliminary data of 79 patients are reported; eligible cases were 51(65%) adenocarcinoma and 28(35%) squamous cell carcinoma, 31(39%) stage II and 48(61%) stage III. Median follow-up was 2.5 years. Higher PD-L1 expression identified cases with worse prognosis (2.5 years OS 58% in high compared with 74% in low expressing tumors), even though without statistical significance. Shorter OS was observed in cases with higher PT CD3+CD8 + (p = 0.015), CD3+CD4 + (p = 0.047) and CD68 + (p = 0.047). These three parameters were put together into a combined IS (2/3 low: low, 2/3 high: high) which confirmed a prognostic stratification of evaluated patients (2.5 years OS 96% vs 63% respectively in low and high IS, p = 0.004), also at multivariate analysis. The prognostic impact of combined IS within each pathologic stage was confirmed. IT T-lymphocytes and macrophages infiltrate did not show a negative prognostic impact; 2.5 years OS of 94% vs 67% (p = 0,033) was observed in highe and lower PT-CD8+/IT-CD8+ ratio, respectively.


The amount of PT T-lymphocytes and macrophages might allow early-stage NSCLC patients prognostic stratification for adjuvant strategy plan, especially within a combined immuno-score including multiple TME actors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Istituto Oncologico Veneto IRCCS.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.